

# **PI-103**

**Catalog No: tcsc0127** 

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

**Size:** 100mg

**Specifications** 

#### CAS No:

371935-74-9

#### Formula:

 $C_{19}H_{16}N_4O_3$ 

#### Pathway:

Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

#### **Target:**

Apoptosis; Autophagy; DNA-PK; mTOR; PI3K

### **Form:** Light green to gray (Solid)

# Purity / Grade:

98.10%

#### Solubility:

DMSO : 10 mg/mL (28.71 mM; Need ultrasonic)

#### **Storage Instruction:**

Storage temp. 2-8°C

Copyright 2021 Taiclone Biotech Corp.



#### **Alternative Names:**

Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

#### **Observed Molecular Weight:**

348.36

## References

[1]. Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009 Jul;8(7):1725-39. [2]. Park S, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase anLeukemia. 2008 Sep;22(9):1698-706.d mTOR, has antileukemicactivity in AmL. Leukemia. 2008 Sep;22(9):1698-706. [3]. López-Fauqued M, et al. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of melanoma cells. Int J Cancer. 2010 Apr 1;126(7):1549-61. [4]. Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110 alpha. Cell. 2006 May 19;125(4):733-47.

# **Product Description**

PI-103 is a potent **PI3K** and **mTOR** inhibitor with **IC**<sub>50</sub>s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110**α, **p110**β, **p110**δ, **p110**γ, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM.

IC50 & Target: IC50: 8 nM (p110α), 88 nM (p110β), 48 nM (p110δ), 150 nM (p110γ), 2 nM (DNA-PK), 20 nM (mTORC1), 83 nM (mTORC2), 26 nM (PI3KC2β), 850 nM (ATR), 920 nM (ATM), ~1  $\mu$ M (PI3KC2α), 2.3  $\mu$ M (hsVPS34), ~50  $\mu$ M (PI4KIIIβ)<sup>[4]</sup>

*In Vitro:* PI-103 exhibits antiproliferative properties in a panel of human cancer cell lines<sup>[1]</sup>. PI-103 is essentially cytostatic for cell lines and induced cell cycle arrest in the G1 phase. In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells <sup>[2]</sup>. PI-103 potently inhibits both the rapamycin-sensitive (mTORC1, IC<sub>50</sub>=20 nM) and rapamycin-insensitive (mTORC2, IC<sub>50</sub>=83 nM) complexes of the protein kinase mTOR<sup>[4]</sup>.

*In Vivo:* PI-103 shows therapeutic activity against a range of human tumor xenografts, exhibiting inhibition of angiogenesis, invasion, and metastasis, as well as direct antiproliferative effects<sup>[1]</sup>. PI-103 induces immunosuppression promoting *in vivo* tumor growth and inhibiting apoptosis. Tumors from PI-103-treated mice shows higher levels of cyclin D1 and more proliferating cells<sup>[3]</sup>.



Copyright 2021 Taiclone Biotech Corp.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.